![ASCO 2022 Conference Coverage](http://media.vumedi.com/thumbs/channel_logo/2022/5/eadfa937-de35-4504-be38-58654669525f.png.200x0_q85.png)
ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 Patient-Reported Outcomes From the Phase 3 HIMALAYA Study of Tremelimumab + Durvalumab in Unresectable HCC
By
ASCO 2022 Conference Coverage
FEATURING
Peter Galle
By
ASCO 2022 Conference Coverage
FEATURING
Peter Galle
65 views
July 9, 2022
Login to view comments.
Click here to Login
GI